Calliditas: Good Long-Term Data Could Boost Tarpeyo Sales (NASDAQ:CALT)


Calliditas Therapeutics (NASDAQ:CALT) just lately reported optimistic long-term information of Tarpeyo (Nefecon/budesonide) in sufferers with IgA nephropathy. The outcomes confirmed the earlier optimistic findings from the section 3 trial and point out a possible disease-modifying impact of Tarpeyo contemplating the preserved

Nefecon's eGFR data - primary analysis

Calliditas Investor Presentation

eGFR percentage benefit of Nefecon

Calliditas investor presentation

Nefecon (Tarpeyo) proteinuria data

Calliditas investor presentation

Safety data from the phase 3 trial of Nefecon (Tarpeyo)

Calliditas investor presentation